GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Concord Drugs Ltd (BOM:538965) » Definitions » Gross-Profit-to-Asset %

Concord Drugs (BOM:538965) Gross-Profit-to-Asset % : 18.08% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Concord Drugs Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Concord Drugs's annualized Gross Profit for the quarter that ended in Dec. 2023 was ₹106.5 Mil. Concord Drugs's average Total Assets over the quarter that ended in Dec. 2023 was ₹589.0 Mil. Therefore, Concord Drugs's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 18.08%.


Concord Drugs Gross-Profit-to-Asset % Historical Data

The historical data trend for Concord Drugs's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Drugs Gross-Profit-to-Asset % Chart

Concord Drugs Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.95 12.27 15.36 31.64 19.27

Concord Drugs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.34 10.29 21.93 23.26 18.08

Competitive Comparison of Concord Drugs's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concord Drugs's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Concord Drugs's Gross-Profit-to-Asset % falls into.



Concord Drugs Gross-Profit-to-Asset % Calculation

Concord Drugs's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Mar. 2023 )/( (Total Assets (A: Mar. 2022 )+Total Assets (A: Mar. 2023 ))/ count )
=110.511/( (564.451+582.31)/ 2 )
=110.511/573.3805
=19.27 %

Concord Drugs's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=106.508/( (589.045+0)/ 1 )
=106.508/589.045
=18.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Concord Drugs Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Concord Drugs's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Concord Drugs (BOM:538965) Business Description

Traded in Other Exchanges
N/A
Address
3-11-451, L B Nagar, Hayatnagar Mandal, Hyderabad, TG, IND, 500074
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers. Geographically, it operates only in India.

Concord Drugs (BOM:538965) Headlines

No Headlines